UI Hospitals and Clinics
A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Participants in this study have recently been diagnosed with a type of leukemia (blood cancer) called chronic myelogenous leukemia (CML). The purpose of this study is to evaluate ponatinib as a potential treatment for patients who have been newly diagnosed with CML. Ponatinib is an experimental anti-cancer drug. This study will compare the effects of ponatinib to another drug called imatinib. Imatinib is approved by the United States Food and Drug Administration (FDA) for treating a variety of human cancers including newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. This study will enroll approximately 530 participants (subjects) in about 175 centers worldwide.
Karen Parrott, 319-353-6347
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.